Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NEW JCM GROUP
300157
5
Shenzhen S-king Intelligent Equipment
688328
US OptionsDetailed Quotes
MRK250502C95000
- 0.03
- 0.000.00%
15min DelayClose Apr 28 16:00 ET
0.00High0.00Low
0.03Open0.03Pre Close0 Volume74 Open Interest95.00Strike Price0.00Turnover59.05%IV14.23%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0167Delta0.0081Gamma2773.00Leverage Ratio-0.0206Theta0.0001Rho46.33Eff Leverage0.0036Vega
Merck & Co Newsroom
9 Health Care Stocks Whale Activity In Today's Session
Unusual Options Activity: CRM, MRK and Others Attract Market Bets, CRM V/OI Ratio Reaches 231.7
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Today's Analyst Rating | Apple Price Target Raised to $235 by Morgan Stanley, HSBC Cuts Its Price Target Cut on Merck & Co to $100
HSBC Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $100
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Merck's Keytruda Improves Head and Neck Cancer Survival by 34% in Study
Merck Germany announced the acquisition of the USA Biotechnology company SpringWorks for 3.9 billion dollars.
German Medical Care and materials group Merck (Merck KGaA) announced on Monday that it has reached an agreement to acquire the USA biotechnology company SpringWorks Therapeutics for an equity value of $3.9 billion, aiming to strengthen its oncology business. Merck stated that after deducting the Cash held by SpringWorks, the cash acquisition price of $47 per share represents an equity value of approximately $3.9 billion, equivalent to an enterprise value of $3.4 billion (€3 billion). Last week, Merck stated that the two companies were in late-stage negotiations regarding the Quote of approximately $47 per share.
Agreement reached! Merck acquires SpringWorks (SWTX.US) for $3.9 billion.
Merck KGaA announced on Monday that it has reached an agreement to acquire the USA biotechnology company SpringWorks Therapeutics for a share value of $3.9 billion.
Express News | Merck & Co Inc : HSBC Cuts Target Price to $100 From $115
Jianyin International: Raised AKESO's Target Price to 120 Hong Kong dollars, maintaining an "outperform the market" rating.
Jianyin International released a Research Report stating that it raised the Target Price for AKESO (09926) by 33.3%, from HKD 90 to HKD 120, mainly reflecting the upward revision of the company's earnings forecast and the high likelihood of the company's lung cancer pharmaceuticals achieving success in China and overseas. The rating of "Outperform Market" is maintained. The bank pointed out that AKESO has a solid fundamental outlook. On April 18, AKESO announced that its human IgG1 antibody (AK101), Ebdarokimab, has been approved for the Chinese market for the treatment of moderate to severe plaque psoriasis. This success prompted the bank to adjust AKESO's outlook.
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
KEYTRUDA (Pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
Analysts Have Made A Financial Statement On Merck & Co., Inc.'s (NYSE:MRK) First-Quarter Report
Merck & Co. Inc. Stock Climbs 3.6%, Outperforms Competitors
Merck & Co Options Spot-On: On April 25th, 114.48K Contracts Were Traded, With 685.79K Open Interest
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now